Monoclonal antibody and other Fc-containing molecules can be constructed using the disclosed variations in the Fc region causing increased resistance to host and pathogen-derived proteases and exhibiting the ability to interact with Fey receptors and initiate complement directed cytotoxicity as demonstrated by functional assays. The Fc-containing molecules are useful in the treatment of various diseases and disorders wherein FcR-driven host functions contribute activity.
